Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.

Purpose: Recent epidemiological evidence has suggested that use of lipid-lowering medications, particularly statins, was associated with reduced cardiovascular disease (CVD) events and persistent physical disability in healthy older adults. However, the comparative efficacy of different statins in t...

Descripción completa

Detalles Bibliográficos
Publicado en:European Journal of Clinical Pharmacology Vol. 78; no. 3; pp. 467 - 477
Autores principales: Zhou, Zhen, Curtis, Andrea J., Ernst, Michael E., Ryan, Joanne, Zoungas, Sophia, Wolfe, Rory, McNeil, John J., Murray, Anne M., Reid, Christopher M., Chowdhury, Enayet K., Woods, Robyn L., Tonkin, Andrew M., Nelson, Mark R.
Formato: algorithm research tables/charts Journal Article
Publicado: Springer Nature Mar2022
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=155080938&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 155080938
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        00316970
        NP9
      jtl: European Journal of Clinical Pharmacology
      issn: 00316970
      maglogo: N
    pubinfo:
      dt: Mar2022
      vid: 78
      iid: 3
      pid: 237
      pub: Springer Nature
      place: New York, New York
    artinfo:
      ui:
        155080938
        153259260
        155080938
        155080938
        10.1007/s00228-021-03239-1
        155080938
      ppf: 467
      ppct: 10
      formats:
        fmt:
          – @attributes:
              type: T
          – @attributes:
              type: P
      tig:
        atl: Comparison of statins for primary prevention of cardiovascular disease and persistent physical disability in older adults.
      aug:
        au:
          Zhou, Zhen
          Curtis, Andrea J.
          Ernst, Michael E.
          Ryan, Joanne
          Zoungas, Sophia
          Wolfe, Rory
          McNeil, John J.
          Murray, Anne M.
          Reid, Christopher M.
          Chowdhury, Enayet K.
          Woods, Robyn L.
          Tonkin, Andrew M.
          Nelson, Mark R.
        affil: Menzies Institute for Medical Research, University of Tasmania, TAS, 17 Liverpool Street, 7000, Hobart, Australia
      sug:
        subj:
          Cardiovascular Diseases Prevention and Control
          Statins Therapeutic Use
          Functional Status
          Human
          Aged
          Aged, 80 and Over
          Post Hoc Analysis
          Cox Proportional Hazards Model
          Descriptive Statistics
          Confidence Intervals
          Aged: 65+ years
          Aged, 80 & over
      ab: Purpose: Recent epidemiological evidence has suggested that use of lipid-lowering medications, particularly statins, was associated with reduced cardiovascular disease (CVD) events and persistent physical disability in healthy older adults. However, the comparative efficacy of different statins in this group remains unclear. This study aimed to compare different forms of statins in their associations with CVD and physical disability in healthy older adults. Methods: This post hoc analysis included data from 5981 participants aged ≥ 70 years (≥ 65 if US minorities; median age:74.0) followed for a median of 4.7 years, who had no prior CVD events or physical disability and reported using a statin at baseline. The incidence of the composite and components of major adverse cardiovascular events and persistent physical disability were compared across different statins according to their type, potency, and lipophilicity using multivariable Cox proportional-hazards models. Results: Atorvastatin was the most used statin type at baseline (37.9%), followed by simvastatin (29.6%), rosuvastatin (25.5%), and other statins (7.0%, predominantly pravastatin). In comparisons of specific statins according to type and lipophilicity (lipophilic vs. hydrophilic statin), observed differences in all outcomes were small and not statistically significant (all p values > 0.05). High-potency statin use (atorvastatin and rosuvastatin) was marginally associated with lower risk of fatal CVD events compared with low-/moderate-potency statin use (hazard ratio: 0.59; 95% confidence interval: 0.35, 1.00). Conclusion: There were minimal differences in CVD outcomes and no significant difference in persistent physical disability between various forms of statins in healthy older adults. Future investigations are needed to confirm our results.
      pubtype: Academic Journal
      doctype:
        algorithm
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N